0001213900-24-052251.txt : 20240613 0001213900-24-052251.hdr.sgml : 20240613 20240613082827 ACCESSION NUMBER: 0001213900-24-052251 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240613 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTERITY THERAPEUTICS LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 241040069 BUSINESS ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 BUSINESS PHONE: 61 3 9349 4906 MAIL ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 FORMER COMPANY: FORMER CONFORMED NAME: PRANA BIOTECHNOLOGY LTD DATE OF NAME CHANGE: 20010105 6-K 1 ea0207804-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2024

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒     Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1   Alterity to Present at Hidden Gems in Life Sciences Webinar

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
   
  By:  /s/ Geoffrey P. Kempler
    Geoffrey P. Kempler
    Chairman

 

Date: June 13, 2024

 

 

2

 

 EX-99.1 2 ea020780401ex99-1_alterity.htm ALTERITY TO PRESENT AT HIDDEN GEMS IN LIFE SCIENCES WEBINAR

Exhibit 99.1

 

 

 

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

 

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 13 June 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States.

 

Details are listed below and registration is required.

 

Webcast details

 

AUSTRALIA PARTICIPANTS:

 

  Date: Thursday, 13 June 2024
  Time: 1:30 p.m. AEST (Sydney/Melbourne)

 

UNITED STATES PARTICIPANTS:

 

  Date: Wednesday, 12 June 2024
  Time: 8:30 p.m. Pacific Time
    11:30 p.m. Eastern Time

 

To join the presentation, please click the webinar link here.

 

Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.

 

A recording of the webinar will be made available on the Alterity Therapeutics website after the event, which you can access here: www.alteritytherapeutics.com.

 

About Alterity Therapeutics Limited

 

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

 

Authorisation & Additional information

 

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

 

Investor and Media Contacts:

 

Australia

Hannah Howlett

we-aualteritytherapeutics@we-worldwide.com

+61 450 648 064

 

U.S.

Remy Bernarda

remy.bernarda@iradvisory.com

+1 (415) 203-6386

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end